SIGA Technologies Logo
US8269171067
919473
SIGA

SIGA Technologies

Prognose

Køb
  1
Behold
  0
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • SIGA Technologies pays special dividend of $0.60 per share

    The board of directors of SIGA Technologies has approved a cash dividend of $0.60 per common share, payable on April 23, 2026 to shareholders of record at the close of trading on April 7, 2026. The payout matches the special dividend announced in April 2025 and, according to InvestingPro, represents a yield of about 12%. The company shows a high liquidity ratio (current ratio 11.83), while the stock, at $4.81, is trading near its 52-week low and has fallen roughly 46% over the past six months. SIGA Technologies is in the commercialization phase and focuses on drugs for the treatment and prevention of infectious diseases, particularly orthopoxviruses. » Mere på de.investing.com


  • SIGA Technologies posts annual profit of $23 million despite quarterly loss

    SIGA Technologies reported 2025 annual revenue of $95 million and a net profit of $23 million, with a cash balance of $155 million and no debt. However, in the fourth quarter the company posted a loss per share of -$0.08, highlighting quarterly volatility due to irregular government procurement. Investor reactions were mixed: the stock fell in after-hours trading but recovered in pre-market trading. Remaining risks include regulatory uncertainty in Europe for the Mpox indication and strong dependence on U.S. government contracts. » Mere på de.investing.com


  • SIGA Technologies reports strong 2025 results and remains debt-free

    SIGA Technologies recorded total revenue of $95 million in 2025, including $88 million in product revenue, and net income of $23 million (earnings per share $0.32). The company holds $155 million in cash, is debt-free, and delivered TPOXX worth $79 million to the U.S. government. Outstanding government orders of $26 million for 2026, plus $27 million in grants for pediatric and intravenous formulations, underpin the optimistic outlook. » Mere på de.investing.com


  • SIGA Technologies: stock falls despite strong revenue growth in third quarter

    SIGA Technologies reported product revenues of $86 million for the first nine months (prior year $54 million), driven by strong TPOXX sales. The company holds $172 million in cash and is debt-free; net income for the nine months amounted to $29 million. The stock fell 3.08% to $8.07 in after-hours trading following the release of the figures. SIGA plans an FDA filing for TPOXX for post-exposure prophylaxis, is working on a pediatric formulation and expects international sales in 2026, but sees risks from procurement delays and regulatory hurdles. » Mere på de.investing.com


  • SIGA Technologies reports stable quarterly results and remains financially solid

    SIGA Technologies posted stable revenues of $79 million and earnings per share of $0.49 in the second quarter of 2025, while the stock price remained nearly unchanged. The company remains debt-free with a cash balance of $182 million and plans to submit new approval applications for its TPOXX products. However, international business development remains volatile, and reliance on US government contracts poses risks. » Mere på de.investing.com

I 2026 har SIGA Technologies allerede udloddet 0,51 € i udbytte. Den seneste udlodning fandt sted i april.

Virksomhedstal

I det seneste kvartal havde SIGA Technologies en omsætning på 1,16 mio. € og et nettoresultat på -2,55 mio. €

(EUR) september 2026
YoY
Omsætning 1,16 mio. 47,92 %
Bruttofortjeneste 654,46 t 52,53 %
Nettoresultat -2,55 mio. 52,91 %
EBITDA -4,84 mio. 30,85 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
156,84 mio. €
Antal aktier
71,86 mio.
Højeste/laveste i 52 uger
6,48 € - 2,16 €
Udbytteafkast
19,83 %
Udbytte TTM
0,51 €
Beta
1,02
P/E (PE Ratio)
374,22
PEG (PEG Ratio)
-3,43
K/I (PB Ratio)
1,05
P/S (PS Ratio)
3,29

Virksomhedsprofil

SIGA Technologies, Inc., et kommercielt fase-virksomhed inden for lægemidler, fokuserer på sundhedssikkerhed og markeder for infektionssygdomme i USA. Dets vigtigste produkt er TPOXX, et oralt antiviralt lægemiddel til behandling af kopper hos mennesker, forårsaget af variolavirus. SIGA Technologies, Inc. har et strategisk partnerskab med Cipla Therapeutics om at levere vedvarende innovation og adgang til antibakterielle lægemidler, primært mod biotrusler. Virksomheden blev stiftet i 1995 og har hovedkontor i New York, New York.

Navn
SIGA Technologies
CEO
Diem Nguyen
Hjemsted New York City, ny
USA
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
10.09.1997
Medarbejdere 49

Tickersymboler

Børs Symbol
NASDAQ
SIGA
🍪

Parqet  bruger cookies. Læs mere